Dear ALS community, We are pleased to share that Prilenia has entered into a collaboration and license agreement with Ferrer for the commercialization and co-development of pridopidine in Europe and… More >>

TRICALS, in collaboration with King’s College London and Macquarie University, announced that the global Phase 3 placebo-controlled Lighthouse II study was terminated after the interim analysis did not demonstrate an… More >>

Reldesemtiv in Amyotrophic Lateral Sclerosis Results From the COURAGE-ALS Randomized Clinical Trial Key Points Question Does orally administered reldesemtiv slow disease progression in amyotrophic lateral sclerosis (ALS)? Findings A Study to Evaluate… More >>

Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort Company Expects to Initiate Enrollment of Second Dose Cohort in the First Quarter… More >>

The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital announced topline results from Regimen F of the HEALEY ALS Platform Trial evaluating fosigotifator (ABBV-CLS-7262) in people… More >>

The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital announced topline results from an analysis of Regimen G evaluating DNL343, an eIF2B agonist developed by Denali… More >>

Corcept Therapeutics, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol,… More >>

– Study failed to meet primary and secondary efficacy endpoints – PTC Therapeutics announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing… More >>